Development of bronchiolitis obliterans syndrome in recipients of heart-lung transplantation--early risk factors.

Given the internationally recognized definition of bronchiolitis obliterans syndrome (BOS) and longer follow up of heart-lung transplant recipients, it is possible to establish some of the major risk factors for development and progression of BOS. Between April 1984 and 31 December 1993, 157 patients underwent heart-lung transplantation; 126 survived at least six months after operation and so were at risk of developing BOS. The following early risk factors were assessed for development of BOS grade 1 (21-35% decline in FEV1) and progression from grade 1 to grade 2 (36-50% decline in FEV1): age, gender and underlying diagnosis of the recipient, evidence of acute rejection and cytomegalovirus (CMV) infection within 6 months of operation, peak FEV1 achieved, age and gender of the donor, cold ischemic time of the graft, and matching of CMV serological status and HLA antigens of donor and recipient. The number of acute rejection episodes observed remained the single most important determinant of development of BOS grade 1 (relative risk 1.17 (1.06, 1.29), P=0.002) and progression to BOS grade 2 (relative risk 1.58 (1.02, 2.46), P=0.03). No other factors were significantly related to development or progression of BOS, although both evidence of CMV infection and disease and the number of HLA mismatches increased the risk. Bronchiolitis obliterans syndrome is a major problem for medium-to-long-term survivors of cardiothoracic transplantation. Acute rejection early after transplantation is a sensitive prognostic indicator of subsequent functional decline and requires prompt attention.

[1]  A. Gascoigne,et al.  ORGANIZING PNEUMONIA FOLLOWING PULMONARY TRANSPLANTATION AND THE DEVELOPMENT OF OBLITERATIVE BRONCHIOLITIS1 , 1994, Transplantation.

[2]  G Opelz,et al.  The influence of HLA compatibility on graft survival after heart transplantation. The Collaborative Transplant Study. , 1994, The New England journal of medicine.

[3]  G. Berry,et al.  The diagnosis of obliterative bronchiolitis after heart-lung and lung transplantation: low yield of transbronchial lung biopsy. , 1993, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[4]  R. Bolman,et al.  ARE MULTIPLE IMMUNOPATHOGENETIC EVENTS OCCURRING DURING THE DEVELOPMENT OF OBLITERATIVE BRONCHIOLITIS AND ACUTE REJECTION? , 1993, Transplantation.

[5]  S. Yousem Lymphocytic Bronchitis/Bronchiolitis in Lung Allograft Recipinets , 1993, The American journal of surgical pathology.

[6]  B. Griffith,et al.  Pediatric lung transplantation. The years 1985 to 1992 and the clinical trial of FK 506. , 1993, The Journal of thoracic and cardiovascular surgery.

[7]  R. Giudicelli,et al.  Double-lung transplantation in children: a report of 20 cases. The Joint Marseille-Montréal Lung Transplant Program. , 1993, The Annals of thoracic surgery.

[8]  R. Nakhleh,et al.  Obliterative bronchiolitis after lung transplantation: a fibroproliferative disorder associated with platelet-derived growth factor. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[9]  A. Gascoigne,et al.  The immunohistopathology of obliterative bronchiolitis following lung transplantation. , 1992, Transplantation.

[10]  A. Khaghani,et al.  Intermediate-term results of heart-lung transplantation for cystic fibrosis , 1992, The Lancet.

[11]  J. Miller,et al.  Pulmonary transplantation: Early and late results , 1992 .

[12]  D. Royston High-dose aprotinin therapy: a review of the first five years' experience. , 1992, Journal of cardiothoracic and vascular anesthesia.

[13]  R. Bolman,et al.  DIFFERENTIATION OF CLASS I‐ AND CLASS II‐DIRECTED DONOR‐SPECIFIC ALLOREACTIVITY IN BRONCHOALVEOLAR LAVAGE LYMPHOCYTES FROM LUNG TRANSPLANT RECIPIENTS1 , 1992, Transplantation.

[14]  B. Griffith,et al.  Does histologic acute rejection in lung allografts predict the development of bronchiolitis obliterans? , 1991, Transplantation.

[15]  L. Sharples,et al.  Risk factors for obliterative bronchiolitis in heart-lung transplant recipients. , 1991, Transplantation.

[16]  S. Marshall,et al.  Heart-lung transplantation in infants, children, and adolescents. , 1991, Journal of pediatric surgery.

[17]  B. Griffith,et al.  Cytomegalovirus serologic status and postoperative infection correlated with risk of developing chronic rejection after pulmonary transplantation. , 1991, Transplantation.

[18]  R. Dowling,et al.  HLA-class II antigen expression in human heart-lung allografts. , 1990, Transplantation.

[19]  J. Theodore,et al.  Lung transplantation comes of age. , 1990, The New England journal of medicine.

[20]  J. Scott,et al.  The use of home spirometry in detecting acute lung rejection and infection following heart-lung transplantation. , 1990, Chest.

[21]  M. Yacoub,et al.  Expression of MHC antigens in normal human lungs and transplanted lungs with obliterative bronchiolitis. , 1989, Transplantation.

[22]  B. Griffith,et al.  Efficacy of transbronchial lung biopsy in the diagnosis of bronchiolitis obliterans in heart-lung transplant recipients. , 1989, Transplantation.

[23]  R. Yolken,et al.  INFANTILE GASTROENTERITIS ASSOCIATED WITH EXCRETION OF PESTIVIRUS ANTIGENS , 1989, The Lancet.

[24]  T. Higenbottam,et al.  Transbronchial lung biopsy for the diagnosis of rejection in heart-lung transplant patients. , 1988, Transplantation.

[25]  T. Higenbottam,et al.  The diagnosis of lung rejection and opportunistic infection by transbronchial lung biopsy. , 1987, Transplantation proceedings.

[26]  E. Robin,et al.  Obliterative bronchiolitis after heart-lung transplantation: apparent arrest by augmented immunosuppression. , 1987, Annals of internal medicine.

[27]  S. Yousem,et al.  Pathologic pulmonary alterations in long-term human heart-lung transplantation. , 1985, Human pathology.

[28]  S. Yousem,et al.  Post-transplant obliterative bronchiolitis and other late lung sequelae in human heart-lung transplantation. , 1984, Chest.

[29]  S. Hunt,et al.  Heart-lung transplantation: successful therapy for patients with pulmonary vascular disease. , 1982, The New England journal of medicine.

[30]  J. Wallwork,et al.  Significance of graft coronary artery disease in heart-lung transplant recipients. , 1995, Transplantation proceedings.

[31]  J. Scott,et al.  Risk factors for survival following combined heart-lung transplantation. The first 100 patients. , 1994, Transplantation.

[32]  G. Patterson,et al.  A working formulation for the standardization of nomenclature and for clinical staging of chronic dysfunction in lung allografts. International Society for Heart and Lung Transplantation. , 1993, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[33]  G. Patterson,et al.  Redo lung transplantation: a North American-European experience. , 1993, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.